{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:43:55Z","timestamp":1763142235236},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis C virus (HCV) represents a formidable menace to human health, necessitating urgent attention. The objective of this study was to assess the efficacy and safety of HCV health management in the city of Guigang which consists of five districts, employing a comprehensive multi\u2010modal approach. The study systematically carried out HCV screening in Guigang city which consists of five districts, such as Gangbei District, Gangnan District, Guiping District, Qintang District, and Pingnan District from 1 January 2016 to 30 December 2022. The target population consisted of individuals residing in these aforementioned districts, falling within the age range of 30\u201375\u2009years. A multidisciplinary HCV management team was established to deliver anti\u2010HCV screening, diagnosis, and direct\u2010acting antiviral (DAA) therapy. The primary outcome of interest was the achievement of sustained virologic response (SVR). A total of 2489 individuals were included as the target population, with 1694 individuals residing in Gangbei District, 202 in Gangnan District, 111 in Qintang District, 167 in Pingnan District, and 315 in Guiping District. Out of these individuals, 2478 were subjected to anti\u2010HCV screening. The screening rates varied across the districts, ranging from a peak of 99.55% in Guigang City to a nadir of 98.41% in Guiping District. Remarkably, within Guigang City, a noteworthy enhancement was observed in the HCV\u2010RNA diagnosis rate from 23.4% prior to program implementation to a remarkable 100% following 7\u2009years of intervention and management. Furthermore, the diagnosis and treatment coordination rate experienced a substantial improvement, rising from 26.8% before program inception to 80%. Importantly, a total of 1180 individuals affected by hepatitis C were successfully cured, equating to a 100% cure rate. Logistic regression analysis revealed a significant association between serological status and factors such as Aging, bilirubin, and glutamic oxalacetic transaminase. The findings from our investigation unveil a pioneering HCV management model, exemplified by the Guigang model, which has contributed crucially to HCV microclearance efforts and serves as an invaluable reference for future initiatives.<\/jats:p>","DOI":"10.1111\/jvh.13922","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T04:53:12Z","timestamp":1707367992000},"page":"208-215","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronic viral hepatitis C micro\u2010elimination program using telemedicine in Guigang city"],"prefix":"10.1111","volume":"31","author":[{"given":"Riying","family":"Lv","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases Guigang City People's Hospital  Guigang Guangxi China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmeng","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Guigang City People's Hospital  Guigang Guangxi China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyao","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Guigang City People's Hospital  Guigang Guangxi China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menglan","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Guigang City People's Hospital  Guigang Guangxi China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shixiong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Guigang City People's Hospital  Guigang Guangxi China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13480"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00386-7"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00774-0"},{"key":"e_1_2_8_5_1","first-page":"2","article-title":"Viral hepatitis C, active component, U.S. armed forces, 2011\u20132020","volume":"29","author":"Stahlman SL","year":"2022","journal-title":"MSMR"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14840"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.26444\/aaem\/75928"},{"key":"e_1_2_8_8_1","first-page":"9270","article-title":"Epidemiology and natural history of hepatitis C virus infection","volume":"20","author":"Lee MH","year":"2014","journal-title":"World J Gastroenterol"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i4.1357"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02537.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.107"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.06.033"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2463"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2021.0193"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2018.372"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-016-4291-2"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.04.003"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2174\/156652412798376152"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-017-4280-y"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323277"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-019-0861-y"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25052"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05435-3"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.07.033"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.09.019"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2020.0150"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13477"},{"key":"e_1_2_8_28_1","first-page":"623","article-title":"Telemedicine, time to change the paradigm of hepatitis C management: improve access and reduce costs in reference to: chronic viral hepatitis C micro\u2010elimination program using telemedicine. The Mexican experience, by P\u00e9rez Hern\u00e1ndez et\u00a0al","volume":"113","author":"Cabezas J","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18073694"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13959"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2015.1129388"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009370"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.15523"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30139-0"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.004"},{"key":"e_1_2_8_36_1","first-page":"3","article-title":"Laboratory evaluation of the patient with liver disease","volume":"8","author":"Astegiano M","year":"2004","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.09.032"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T07:00:46Z","timestamp":1710572446000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/jvh.13922"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13922","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]},"assertion":[{"value":"2023-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}